Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.

<h4>Background</h4>Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Katsuhiro Yoshikawa, Mitsuaki Ishida, Hirotsugu Yanai, Koji Tsuta, Mitsugu Sekimoto, Tomoharu Sugie
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/0312115e02ca406ba35c64337ec308fd
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!